Pages that link to "Q81629286"
Jump to navigation
Jump to search
The following pages link to Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone (Q81629286):
Displaying 50 items.
- KRAS mutational analysis for colorectal cancerApplication: Pharmacogenomic (Q21128654) (← links)
- PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis (Q26992267) (← links)
- Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer (Q27027648) (← links)
- KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 (Q27851532) (← links)
- Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status (Q28082816) (← links)
- 1, 9-Pyrazoloanthrones Downregulate HIF-1α and Sensitize Cancer Cells to Cetuximab-Mediated Anti-EGFR Therapy (Q28476652) (← links)
- The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis (Q30240061) (← links)
- Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer (Q33391425) (← links)
- Cryopreservation of human colorectal carcinomas prior to xenografting (Q33628095) (← links)
- K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011. (Q33703112) (← links)
- Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine (Q33723645) (← links)
- BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer (Q33726858) (← links)
- Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer (Q33983663) (← links)
- Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer (Q34239801) (← links)
- KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer (Q34269163) (← links)
- KRAS mutation testing in metastatic colorectal cancer (Q34643960) (← links)
- Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3 (Q34659512) (← links)
- The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis (Q34776118) (← links)
- Establishment and characterization of cell lines from chromosomal instable colorectal cancer (Q34827208) (← links)
- Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. (Q35009672) (← links)
- A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity (Q35146077) (← links)
- A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy (Q35584153) (← links)
- Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review. (Q35817101) (← links)
- PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. (Q35953893) (← links)
- KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis (Q36039967) (← links)
- Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer (Q36084851) (← links)
- KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer (Q36089917) (← links)
- Comparative genomic analysis of primary versus metastatic colorectal carcinomas. (Q36157662) (← links)
- Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review (Q36337063) (← links)
- Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer (Q36402296) (← links)
- Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models (Q36629392) (← links)
- MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. (Q36629393) (← links)
- Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience (Q36849652) (← links)
- Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer (Q36964450) (← links)
- Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer (Q37040644) (← links)
- Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice (Q37132680) (← links)
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash (Q37340624) (← links)
- Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer (Q37378581) (← links)
- Drug development in advanced colorectal cancer: challenges and opportunities (Q37428176) (← links)
- Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. (Q37443898) (← links)
- Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. (Q37468876) (← links)
- Tumor Take Rate Optimization for Colorectal Carcinoma Patient-Derived Xenograft Models (Q37479229) (← links)
- Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. (Q37525272) (← links)
- Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients (Q37636844) (← links)
- KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy (Q37638365) (← links)
- Panitumumab: an arrow on target (Q37739911) (← links)
- KRAS and BRAF: drug targets and predictive biomarkers (Q37815135) (← links)
- Implementing prognostic and predictive biomarkers in CRC clinical trials (Q37842126) (← links)
- Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer (Q37903703) (← links)
- Mechanism of EGER-related cancer drug resistance (Q37912983) (← links)